Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2020 / Aug / Capturing Cancer Through CTCs
Digital and computational pathology Liquid biopsy Precision medicine Software and hardware

Capturing Cancer Through CTCs

Machine learning can help optimize liquid biopsy for rare circulating tumor cells

By Michael Schubert 08/19/2020 Quick Read (pre 2022) 1 min read

Share

What if you could offer patients with cancer all the benefits of a biopsy – without the biopsy? That compelling idea – precision medicine with no need for invasive investigations – is what makes liquid biopsy such an attractive prospect. Unfortunately, there’s a catch; circulating tumor cells (CTCs) are rare, presenting a detection challenge whose only solutions can be difficult and time-consuming. To expand the available options, one research collaboration has taken a new direction: computer assistance.

Unlike existing methods, the new approach requires no labeling or complicated microscopic techniques. Instead, a machine learning algorithm examines standard, low-resolution brightfield microscopy images to distinguish between CTCs and other cells (1). The scientists creating it ran two separate experiments: one on cultured cancer cell lines with a training set of 1,745 single-cell images; another on patient CTCs with a training set of just 95 images. The result? The algorithm exhibited an overall accuracy of 97.5 percent in the first experiment and 88 percent in the second.

“This study, though small, demonstrates that our method can achieve high accuracy on the identification of rare CTCs without the need for advanced devices or expert users,” said senior author Yaling Liu in a recent press release (2). “With more data becoming available in the future, the machine learning model can be further improved and serve as an accurate and easy-to-use tool for CTC analysis.”

So what’s next for the researchers? They’re not only training their algorithm with additional data, but also refining it to examine mutations in the DNA of CTCs. In addition, they’re working on a microfluidic device to better capture and release CTCs (3) – all with the goal of fast, accurate, and minimally invasive personalized medicine for patients with challenging cancers.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. S Wang et al., Sci Rep, 10, 12226 (2020). PMID: 32699281.
  2. Lehigh University (2020). Available at: https://bit.ly/3g5eNV5.
  3. Lehigh University (2020). Available at: https://bit.ly/3azhc9j.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Global Referral
Digital and computational pathology
Global Referral

January 12, 2024

10 min read

How digital pathology is transforming the delivery of remote second opinions

Cracking Colon Cancer
Digital and computational pathology
Cracking Colon Cancer

January 25, 2024

1 min read

How a new clinically approved AI-based tool enables rapid microsatellite instability detection

The (Pathology) IT Crowd?
Digital and computational pathology
The (Pathology) IT Crowd?

December 30, 2021

5 min read

The pathologist’s guide to IT considerations for digitization

Defining the Next Generation of NGS
Digital and computational pathology
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.